Calvin Scott Recalls Hydrochlorothiazide Tablets Due to Packaging Defect
Calvin Scott & Co. is recalling Hydrochlorothiazide 25mg tablets because light-sensitive products were repackaged in transparent pouches.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a packaging defect (transparent pouches for light-sensitive drugs) without reported injuries or illnesses, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Calvin Scott & Company, Inc. is recalling Hydrochlorothiazide (HCTZ) Orange Tabs 25mg, manufactured by Unichem Pharmaceuticals. The recall involves Lot # 19260H with an expiration date of 1/21. The product was distributed nationwide within the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the light-sensitive drug products were repackaged in transparent or partially transparent pouches, which may not provide adequate protection from light.
Consumers who have this specific lot of Hydrochlorothiazide should stop using it and contact their pharmacist or healthcare provider for guidance on replacement medication.
The recalled product
- Product
- Hydrochlorothiazide (HCTZ) Orange Tabs 25mg, Distributed by: Calvin Scott & Co., Inc. Albuquerque, NM 87123 Manufactured by Unichem Pharmaceuticals, NDC 29300-0128-10
- Manufacturer
- Calvin Scott & Company, Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 19260H
- Exp. Date: 1/21
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 19 recalled by Calvin Scott & Company, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 19 products in this recall →Related recalls
Same manufacturer · Calvin Scott & Company, Inc.
See all →- ModerateBenzphetamine tablets recalled due to label mix-up with Benzonatate
FDA (Drugs) · 2022-06-01
- SevereBenzonatate 100mg Capsules Label Mix-up — Wrong Medication in Bottles
FDA (Drugs) · 2022-06-01
- ModerateCalvin Scott Recalls Diethylpropion Tablets Due to Stability Deviations
FDA (Drugs) · 2020-10-14
- ModerateCalvin Scott Recalls Diethylpropion Tablets Due to Missing Stability Studies
FDA (Drugs) · 2020-10-14
- ModerateCalvin Scott Recalls Phentermine Capsules Due to Stability Study Deviations
FDA (Drugs) · 2020-10-14
Same hazard · packaging defect
See all →- HighEmbosphere Microspheres Recalled Due to Packaging Sterility Concerns
FDA (Devices) · 2026-10-07
- ModerateAmneal Recalls Estradiol Gel Packets Due to Empty or Partially Full Containers
FDA (Drugs) · 2026-10-07
- HighCardinal Health Recalls Presource Convenience Kits Due to Seal Defects
FDA (Devices) · 2026-09-30
- ModerateAVID Medical Recalls Halyard IV Start Kits Due to Packaging Seal Issues
FDA (Devices) · 2026-09-30
- HighCardinal Health Recalls Presource Convenience Kits Due to Potential Seal Defects
FDA (Devices) · 2026-09-30
Similar recalls
- SevereTeva Recalls Valsartan and Hydrochlorothiazide Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-01
- SevereNuCare Recalls Valsartan/HCTZ Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-15
- LowQualitest Recalls HydrOXYzine Tablets Due to Unreadable Identification Codes
FDA (Drugs) · 2015-07-22
- HighUnichem Recalls Hydrochlorothiazide Tablets Due to Foreign Tablet Presence
FDA (Drugs) · 2015-09-02
- SevereRemedyRepack Recalls Valsartan/HCTZ Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-08
- ModerateAidapak Recalls Hydrochlorothiazide Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22